Rhizome AI
YC W26New York City, US · Founded 2025 · Delaware corporation · 1 employees · 1 known investors
Rhizome AI provides an AI research platform that answers regulatory and clinical questions by citing documents from health authority databases across multiple markets, with built-in hallucination prevention. The product serves pharmaceutical companies, consultants, and researchers who need to understand regulatory positions and guidance from FDA, EMA, and other regional authorities.
Founders & leadership· Y Combinator alumni (W26)
CM
Chetan MishrainFounder
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$85KraisedJan 2026 · 2 investors · ComputersRule 506(c)
▶$85KraisedJan 2026 · 2 investors · Computers
Rule 506(c)Officers, directors & promoters on the filing
- Chetan MishraExecutive Officer
- Offering amount
- $85K
- Amount sold
- $85K
- Minimum investment
- $85K
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Claude's Corner: Rhizome AI — The FDA Whisperer for Biotech | StartupHub.aistartuphub.ai · 2026
- Rhizome AI - Know what the FDA thinksycombinator.com · 2026
- Rhizome AI Secures $2.5M Pre-Seed Funding to Transform Chemistry with Applied AI Innovation | Signalbasetrysignalbase.com · 2025
- Rhizome AI Funding | Complete Analysis | Extruct AIextruct.ai
